EDIT - Editas Medicine, Inc.
| Previous Close | 25.29 |
| Open | 25.16 |
| Bid | 23.90 x 900 |
| Ask | 24.05 x 1400 |
| Day's Range | 23.94 - 25.64 |
| 52 Week Range | 17.80 - 33.80 |
| Volume | 585,640 |
| Avg. Volume | 673,509 |
| Market Cap | 1.191B |
| Beta (3Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.71 |
- Thomson Reuters StreetEvents
Edited Transcript of EDIT earnings conference call or presentation 6-Aug-19 9:00pm GMT
Q2 2019 Editas Medicine Inc Earnings Call
- GlobeNewswire
Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
Bain Capital Life Sciences Managing Director brings extensive capital markets and diverse life sciences industry experience EMERYVILLE, Calif., Aug. 12, 2019 -- Dynavax.
- American City Business Journals
Bayer buys Cambridge cell therapy startup BlueRock at $1B value
The German-based drug giant has doubled down on one of its previous investments, announcing a deal to acquire the remainder of the stake in BlueRock Therapeutics for $600 million.
Motley FoolEditas Medicine, Inc. (EDIT) Q2 2019 Earnings Call Transcript
EDIT earnings call for the period ending June 30, 2019.
- Zacks
Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
- Motley Fool
Editas Medicine Remains on Track
With a new CEO in place and a groundbreaking "in vivo" dosing study approaching, the gene-editing leader is rightly excited for the future.
- Zacks
Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -16.95% and -61.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Editas Medicine Announces Second Quarter 2019 Results and Update
Cynthia (Cindy) Collins named President and Chief Executive Officer Initiated Brilliance Phase 1/2 clinical trial of EDIT-101(AGN-151587) for LCA10 Patient dosing in.
- American City Business Journals
Legal fight over Broad Institute's patent for CRISPR gene editing flares up again
The legal battle over a method of altering a person’s genes that’s worth billions of dollars escalated this week, with the University of California alleging that the Cambridge-based Broad Institute withheld information in an attempt to deceive U.S. patent officials.
- Motley Fool
Is Intellia Therapeutics a Buy?
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
- GlobeNewswire
Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update
CAMBRIDGE, Mass., July 30, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
- Zacks
Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10
Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the Brilliance Phase 1/2 clinical trial of AGN-151587 (EDIT-101) is open for patient enrollment. AGN-151587 is an experimental medicine under development for the treatment of Leber congenital amaurosis 10 (LCA10), an inherited form of blindness caused by mutations in the CEP290 gene. The clinical trial will be the world’s first in vivo study of a CRISPR-based genome editing medicine, where the editing takes place inside the human body.
- Motley Fool
CRISPR Could Change Medicine, But Not in the Way Wall Street Expects
The gene-editing approach might prove more useful outside the clinic.
- Motley Fool
Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
- Motley Fool
Is Editas Medicine a Buy?
High risk? Definitely. But this small biotech also has the potential for high returns over the long run.
- Zacks
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
- Simply Wall St.
What Kind Of Shareholders Own Editas Medicine, Inc. (NASDAQ:EDIT)?
A look at the shareholders of Editas Medicine, Inc. (NASDAQ:EDIT) can tell us which group is most powerful...
- Motley Fool
How to Invest in Biotech Stocks
Seven simple steps to improving your chances of success in this part of the market.
- Insider Monkey
Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy?
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
- GlobeNewswire
Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced results from a follow-up study to assess two different CRISPR genome editing strategies, one targeting the BCL11A erythroid enhancer (BC11Ae) and one targeting the beta-globin locus, for the treatment of sickle cell disease and beta-thalassemia. The Company reported the data at the 24th Congress of the European Hematology Association in Amsterdam.
- Zacks
Glaxo Inks Genome Research Deal With University of California
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
- Motley Fool
Is the Newest Gene Editing Stock a Buy?
Precision BioSciences raised over $170 million in net proceeds from its initial public offering in late March.
- Zacks
CRISPR Therapeutics Up on Collaboration Expansion by Vertex
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
